Sartorius Stedim Biotech Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Rene Faber

Directeur général

€790.0k

Rémunération totale

Pourcentage du salaire du PDG	68.4%
Durée du mandat du directeur général	1.7yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	8.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Rene Faber a-t-elle évolué par rapport aux bénéfices de Sartorius Stedim Biotech?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	€161m
Jun 30 2024	n/a	n/a	€170m
Mar 31 2024	n/a	n/a	€255m
Dec 31 2023	€790k	€540k	€310m
Sep 30 2023	n/a	n/a	€460m
Jun 30 2023	n/a	n/a	€635m
Mar 31 2023	n/a	n/a	€717m
Dec 31 2022	€578k	€288k	€876m
Sep 30 2022	n/a	n/a	€681m
Jun 30 2022	n/a	n/a	€625m
Mar 31 2022	n/a	n/a	€559m
Dec 31 2021	€901k	€396k	€414m
Sep 30 2021	n/a	n/a	€523m
Jun 30 2021	n/a	n/a	€469m
Mar 31 2021	n/a	n/a	€398m
Dec 31 2020	€742k	€396k	€336m
Sep 30 2020	n/a	n/a	€299m
Jun 30 2020	n/a	n/a	€255m
Mar 31 2020	n/a	n/a	€254m
Dec 31 2019	€784k	€425k	€235m

Rémunération vs marché: La rémunération totale de Rene ($USD 852.95K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 5.18M ).

Rémunération et revenus: La rémunération de Rene a augmenté de plus de 20 % tandis que les bénéfices de l'entreprise ont chuté de plus de 20 % au cours de l'année écoulée.

PDG

Rene Faber (49 yo)

1.7yrs

Titularisation

€790,000

Compensation

Dr. Rene Faber serves as Head of Bioprocess Solutions Division and Member of the Executive Board at Sartorius Aktiengesellschaft since January 01, 2019. He serves as Chief Executive Officer at Sartorius St...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Rene Faber	CEO & DIrector	5.7yrs	€790.00k	pas de données
Joachim Kreuzburg	Non-Executive & Non-Independent Chairman	17.4yrs	€693.15k	0.000010% € 1.8k
Lothar Kappich	Director	7.2yrs	€84.00k	0% € 0
Henri Riey	Director	17.4yrs	€56.00k	0.000010% € 1.8k
Pascale Boissel	Independent Director	5.7yrs	€93.00k	0% € 0
Anne-Marie Graffin	Lead Independent Director	9.6yrs	€91.00k	0.000010% € 1.8k
Susan Dexter	Independent Director	9.6yrs	€84.00k	0.000010% € 1.8k
Romaine Fernandes	Employee Representative Non - Executive Director	1.1yrs	pas de données	0% € 0

8.4yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 56S1 sont considérés comme expérimentés (ancienneté moyenne 8.4 ans).

Sartorius Stedim Biotech Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: €0.26 (vs €0.28 in 3Q 2023)

Second quarter 2024 earnings released: €0.011 loss per share (vs €1.44 profit in 2Q 2023)

Now 22% overvalued

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings released: EPS: €0.58 (vs €1.21 in 1Q 2023)

Upcoming dividend of €0.69 per share

Dividend of €0.69 announced

New minor risk - Profit margin trend

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

First quarter 2023 earnings released: EPS: €1.21 (vs €2.93 in 1Q 2022)

Upcoming dividend of €1.44 per share at 0.5% yield

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €416

New 90-day high: €366

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

New 90-day high: €329

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

New 90-day high: €313

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

New 90-day high - €303

New 90-day high - €273

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

New 90-day high - €259

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen